Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy, Safety, and Prognosis of Multiple Treatment Modalities for Head and Neck Malignant Tumors
ChiCTR2600123756Phase 4Not yet recruiting
- Sponsor
- Ganzhou People's Hospital
- Start
- Apr 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of pembrolizumab in head and neck cancer (HNC) (2 arms), sponsored by Ganzhou People's Hospital. Primary endpoints: Overall Survival and Progression-Free Survival. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
03
Conditions
head and neck cancer (HNC)
Beyond the preview
Go deeper on ChiCTR2600123756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600123756.